Summary
Astra Zenaca's Casodex is a 315 Million $ molecule. What this approval means for Sun is - they will get 6 months exclusivity to market the Generic version before competition enters. Again Sun will have 1st mover advantage here and 60 - 75 million $ bottom line addition is very much possible with a well planned marketing push.
Analysis
As molecules currently leading and being protected by patents lose their patent cover more generics will flood the market.
Generic firm are sitting by the fence ready to jump the day patent expires.
Sun is one such company but Teva is truly leading this race.
This means decrease in sales for some, increase in sales for some & A Lot Cheaper Healthcare for many!!!
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
